Madrigal Pharmaceuticals (MDGL) Competitors

Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Which has more volatility and risk, BIIB or MDGL?

Biogen has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.69, meaning that its stock price is 169% less volatile than the S&P 500.

Is BIIB or MDGL more profitable?

Biogen has a net margin of 16.87% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Biogen's return on equity of 14.98% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	16.87%	14.98%	8.76%
Madrigal Pharmaceuticals	N/A	-71.78%	-53.25%

Does the media prefer BIIB or MDGL?

In the previous week, Biogen had 18 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 31 mentions for Biogen and 13 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.15 beat Biogen's score of 0.84 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	15 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, BIIB or MDGL?

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	1.81	$1.63B	$11.19	10.68
Madrigal Pharmaceuticals	$180.13M	39.22	-$373.63M	-$22.11	-14.47

Does the MarketBeat Community believe in BIIB or MDGL?

Biogen received 1355 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 71.41% of users gave Biogen an outperform vote while only 67.99% of users gave Madrigal Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1818 71.41%	Underperform Votes 728 28.59%
Madrigal Pharmaceuticals	Outperform Votes 463 67.99%	Underperform Votes 218 32.01%

Do insiders & institutionals have more ownership in BIIB or MDGL?

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 22.8% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Do analysts rate BIIB or MDGL?

Biogen presently has a consensus price target of $211.37, suggesting a potential upside of 76.86%. Madrigal Pharmaceuticals has a consensus price target of $409.00, suggesting a potential upside of 27.84%. Given Biogen's higher possible upside, equities analysts plainly believe Biogen is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	18 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.42
Madrigal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Biogen beats Madrigal Pharmaceuticals on 13 of the 19 factors compared between the two stocks.